R&D-Innovation > Projets de R&D labellisés > Drug delivery system

Drug delivery system

  • Neofor - Creation of a technological plateform for the administration of medicines by pulmonary route.

    The aim of NEOFOR project is to establish in Wallonia a consortium who will coordinate multidisciplinary and of technologies groups in order to construct a new SME that will be able – when created – to propose the conception and materialization of original formulations compiled with new medical devices for pulmonary drug administration. The long-term aim is the development and the production following Good Manner of Production of formulation for original molecules a well as appropriated medical devices for the pulmonary delivery of high mass molecular molecules, that is to say proteins, hormones and monoclonal antibodies allowing an innovating therapeutic approach for the treatment of the lung cancer and inflammation diseases. At the end, the project will create a platform getting together the expertise of centers, university labs, small or big and pharmaceutical industries which own different qualifications and that will materialize a new small society (a “start-up”) in charge of the coordination of studies in order to reach this aim.

  • Colvir - Development and validation of a local treatment for cervix cancer resulting from human papillomavirus infection.

    The main objective of the project is the development of an effective and safe local treatment, of the lesions of the cervix induced by HPV infection. This project results from the identification of a medical need and advisability of filling this need with two molecules managed by using the route of the most suitable administration. Within this framework, the specific objectives of the Colvir project are: to obtain the clinical evidence (“proof of concept”) of the effectiveness and the harmlessness of a local treatment using chemo-attractants; to obtain the minimal clinical evidence of the effectiveness and the harmlessness of a local treatment using Cidofovir (an antiviral synthetic molecule). In order to increase the effectiveness of both treatments a sequential application will be also investigated; To develop the adequate formulations directly applied on the cervix.

  • Biofina - Development of inhaled synergetic combinations for the treatment of resistant respiratory infections.

    The aim of BioFiNa is to develop inhaled synergetic combinations for the treatment of resistant respiratory infections. The development of germs which are increasingly resistant to antibiotics is a major public health problem. The arsenal of available antibacterials is no longer sufficient to eradicate chronic respiratory infections due to certain multi-resistant pathogenic agents such as Pseudomonas aeruginosa and Staphylococcus aureus. These respiratory pathologies include, among others, cystic fibrosis, chronic obstructive pulmonary diseases and the various types of pneumonia. The mechanisms giving rise to bacterial resistance in these pathologies very often rely on the presence of biofilms. Biofilms are constituted of  polysaccharides and/or alginate surfaces, resistant to traditional antibacterials, which cover bacterial microcolonies, and which are consequently responsible for the persistence of the germ within the pulmonary parenchyma as well as the chronic underlying inflammation. No drugs exist at the current time that specifically target these biofilms.

  • Deep - Drug-releasing electrode with enhanced properties.

    This project is about the development of an implantable electrode with quantitative drug eluting capacity. Polypyrrole coating of platinum nanostructures forms the basis of this innovative technology. Two lines of application are foreseen. One is to exploit the release of an anti-inflammatory drug in order to limit the tissue reaction around implanted nerves, thus aiming at improving the electrode performances. The second pertains to local treatments requiring precise drug delivery in time and location.

  • Targetum - Chitosan-based Targeting Drug Delivery Systems (Cs-tDDS) and their Proof of Concept.

    Today, the most efficient therapeutic approaches in cancer rely on targeting the tumoral cells in order to enhance the therapeutic effect of the drug, to decrease its dosage and to limit its side effects. The TARGETUM Project aims at building a new class of Chitosan-based targeting Drug Delivery Systems (Cs-tDDS) able to selectively anchor mediators of endothelial cells surface that are involved in the tumor angiogenic process and providing an in vivo Proof of Concept of a promising Cs-tDDS candidate that demonstrates safety and efficacy.